EUR 13.06 For Business Accounts Only

ZHEJIANG CONBA PHARM. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of ZHEJIANG CONBA PHARM. (CN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date November 17, 2017, the closing price was CNY 7.26 and its target price was estimated at CNY 6.83.
Zhejiang CONBA Pharmaceutical Co. Ltd. Class A

Zhejiang Conba Pharmaceutical is engaged in the manufacture and sale of chemical raw material medicines and chemical preparation, chinese prepared medicines, oral liquid, capsule, tablet, non-alcohol beverage, nutrition food, bee products, medical health products, health materials and dressing; the sale of hardware machinery, communication equipment (excluding wireless communication equipment), instrument and meter, medical machinery, computer software, building materials, chemical and textile products, general merchandise, household appliances, cultural products, gymnastic equipment and automobile fittings; the provision of technology consultation services; and the import and export trade.


Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded


Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch